TY - JOUR
T1 - Pc3-secreted microprotein is expressed in glioblastoma stem-like cells and human glioma tissues
AU - Maruyama, Masato
AU - Nakano, Yousuke
AU - Nishimura, Takuya
AU - Iwata, Ryoichi
AU - Matsuda, Satoshi
AU - Hayashi, Mikio
AU - Nakai, Yuki
AU - Nonaka, Masahiro
AU - Sugimoto, Tetsuo
N1 - Funding Information:
Acknowledgments The authors thank Fumio Yamashita and Tetsuji Yamamoto (Kansai Medical University, Osaka, Japan) for technical assistance and Yuki Okada (Kansai Medical University, Osaka, Japan) for expert secretarial work. We appreciate Prof. Ichiro Nakano (University of Alabama at Birmingham) for providing patient-derived GSCs. This work was supported by Grant-in-Aid for Scientific Research (C) (Grant Nos. 25460049, 17K07183) from the Japan Society for the Promotion of Science (JSPS) and the research Grants from Kansai Medical University.
Publisher Copyright:
© 2021 Pharmaceutical Society of Japan. All rights reserved.
PY - 2021/7
Y1 - 2021/7
N2 - Glioblastoma multiforme (GBM) is the most prevalent malignant primary brain tumor with a high recurrence rate. Despite multimodal therapy including surgical resection, chemotherapy, and radiotherapy, the median survival time after the initial diagnosis of GBM is approximately 14 months. Since cancer stem cells (CSCs) are considered the leading cause of cancer recurrence, glioblastoma stem cell-targeted therapy is a promising strategy for the treatment of GBM. However, because CSC heterogeneity has been implicated in the difficulties of CSC-target therapy, more in-depth knowledge of CSC biology is still required to develop novel therapies. In this study, we established single cell-derived tumorspheres from human glioblastoma U87MG cells. One of these tumorspheres, P4E8 clone, showed CSC-like phenotypes, such as self-renewal capacity, expression of CSC markers, resistance to anti-cancer agents, and in vivo tumorigenicity. Therefore, we used P4E8 cells as a cell-based model of glioblastoma stem cells (GSCs). Gene expression analysis using microarray indicated that the most highly expressed genes in P4E8 cells compared to the parental U87MG were PC3-secreted microprotein (MSMP). Furthermore, MSMP was expressed in patient-derived GSCs and human glioma tissues at the protein level, implying that MSMP might contribute to glioma development and progression.
AB - Glioblastoma multiforme (GBM) is the most prevalent malignant primary brain tumor with a high recurrence rate. Despite multimodal therapy including surgical resection, chemotherapy, and radiotherapy, the median survival time after the initial diagnosis of GBM is approximately 14 months. Since cancer stem cells (CSCs) are considered the leading cause of cancer recurrence, glioblastoma stem cell-targeted therapy is a promising strategy for the treatment of GBM. However, because CSC heterogeneity has been implicated in the difficulties of CSC-target therapy, more in-depth knowledge of CSC biology is still required to develop novel therapies. In this study, we established single cell-derived tumorspheres from human glioblastoma U87MG cells. One of these tumorspheres, P4E8 clone, showed CSC-like phenotypes, such as self-renewal capacity, expression of CSC markers, resistance to anti-cancer agents, and in vivo tumorigenicity. Therefore, we used P4E8 cells as a cell-based model of glioblastoma stem cells (GSCs). Gene expression analysis using microarray indicated that the most highly expressed genes in P4E8 cells compared to the parental U87MG were PC3-secreted microprotein (MSMP). Furthermore, MSMP was expressed in patient-derived GSCs and human glioma tissues at the protein level, implying that MSMP might contribute to glioma development and progression.
KW - Cancer stem-like cell
KW - DNA microarray
KW - Glioblastoma
KW - PC3-secreted microprotein
KW - Tumorsphere
UR - http://www.scopus.com/inward/record.url?scp=85109091814&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109091814&partnerID=8YFLogxK
U2 - 10.1248/bpb.b20-00868
DO - 10.1248/bpb.b20-00868
M3 - Article
C2 - 33896885
AN - SCOPUS:85109091814
SN - 0918-6158
VL - 44
SP - 910
EP - 919
JO - Biological and Pharmaceutical Bulletin
JF - Biological and Pharmaceutical Bulletin
IS - 7
ER -